向日葵虚假跨界梦碎，涉嫌误导性陈述被立案

Group 1 - The core issue revolves around the misleading statements in the restructuring plan of Xiangrikui, which has led to an investigation by the China Securities Regulatory Commission (CSRC) [1][4] - The restructuring plan announced in September 2025 aimed to acquire 100% of Xipu Materials and 40% of Beid Pharmaceutical, but it was later revealed that the claimed production bases were "shell companies" without actual production capacity [1][4] - The investigation uncovered that the core products were not self-manufactured but were merely traded for profit, misleading the market regarding asset values [2][4] Group 2 - The restructuring case is marked by complex risks of interest transfer, including undisclosed related-party transactions involving the controlling shareholder's spouse and close relatives of the company's chairman [2][4] - The regulatory response escalated quickly, with the Shenzhen Stock Exchange issuing a notice and the CSRC formally investigating within three weeks, highlighting a new regulatory norm aimed at preventing the injection of poor-quality assets [3][5] - Following the regulatory actions, Xiangrikui's stock price plummeted, triggering a 20% trading halt, resulting in significant losses for investors [5]